Literature DB >> 10972598

Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index.

T Yamada1, J Takeda, N Katori, K Tsuzaki, R Ochiai.   

Abstract

OBJECTIVE: To compare the hemodynamic effects of milrinone during weaning from cardiopulmonary bypass (CPB) in patients with a low pre-CPB cardiac index (CI) <2.5 L/min/m2) and in patients with a high pre-CPB CI (> or =2.5 L/min/m2).
DESIGN: Prospective, randomized, double-blind study.
SETTING: University hospital. PARTICIPANTS: Forty-eight patients scheduled for elective coronary artery bypass graft surgery. INTERVENTION: Patients were divided into 4 groups: (1) low pre-CPB CI/placebo, (2) low pre-CPB CI/milrinone, (3) high pre-CPB CI/placebo, and (4) high pre-CPB CI/milrinone. Patients received a loading dose of 20 microg/kg of milrinone followed by an infusion of 0.2 microg/kg/min or placebo 15 minutes before the anticipated weaning time.
MEASUREMENTS AND MAIN RESULTS: In the low pre-CPB CI/ placebo group, low CIs and high systemic vascular resistances (SVRs) were observed after CPB. High doses of dopamine and dobutamine were needed, and infusion of epinephrine was used in 5 of the 12 patients for hemodynamic support. Milrinone improved CI and reduced SVR in the low pre-CPB CI/milrinone group. Norepinephrine was needed to maintain an adequate systemic blood pressure in 6 of the 12 patients, however. In the high pre-CPB CI/placebo group, satisfactory CIs and SVRs were observed during weaning from CPB with low doses of dopamine and dobutamine. Milrinone significantly increased CI and decreased SVR in the high pre-CPB CI/milrinone group: 10 of the 12 patients had CIs above the upper limit of normal, and 7 patients had SVRs below the lower limit of normal.
CONCLUSION: Milrinone was effective during weaning from CPB in patients with a low pre-CPB CI. Milrinone in combination with norepinephrine was a good alternative to epinephrine for the treatment of myocardial dysfunction after CPB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972598     DOI: 10.1053/jcan.2000.7920

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

1.  Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Tsunehisa Tsubokawa; Syuichi Ishizuka; Kyoko Fukumoto; Kazuyuki Ueno; Ken Yamamoto
Journal:  J Anesth       Date:  2012-10-23       Impact factor: 2.078

Review 2.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  The effect of hemodilution by cardiopulmonary bypass on protein binding of olprinone.

Authors:  Tsunehisa Tsubokawa; Syuichi Ishizuka; Kyoko Fukumoto; Kazuyuki Ueno; Ken Yamamoto
Journal:  J Anesth       Date:  2012-11-23       Impact factor: 2.078

4.  A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients.

Authors:  André Y Denault; Jean S Bussières; Ramiro Arellano; Barry Finegan; Paul Gavra; François Haddad; Anne Q N Nguyen; France Varin; Annik Fortier; Sylvie Levesque; Yanfen Shi; Mahsa Elmi-Sarabi; Jean-Claude Tardif; Louis P Perrault; Jean Lambert
Journal:  Can J Anaesth       Date:  2016-07-28       Impact factor: 6.713

Review 5.  Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.

Authors:  Michael Gillies; Rinaldo Bellomo; Laurie Doolan; Brian Buxton
Journal:  Crit Care       Date:  2004-12-16       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.